Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 9:2020:3972390.
doi: 10.1155/2020/3972390. eCollection 2020.

Natural Products: Review for Their Effects of Anti-HBV

Xuqiang Liu  1   2 , Changyang Ma  1 , Zhenhua Liu  1 , Wenyi Kang  1   2   3
Affiliations
Review

Natural Products: Review for Their Effects of Anti-HBV

Xuqiang Liu et al. Biomed Res Int. .

Abstract

Hepatitis B is a global infectious disease, seriously endangering human health. Currently, there are mainly interferons and nucleoside analogues treatment of hepatitis B in the clinic, which have certain therapeutic effects on hepatitis B, but their side effects and drug resistance are increasingly prominent. Therefore, it is urgently needed to discover and develop new anti-HBV drugs, especially natural products, which have novel, high efficiency, and low toxicity anti-HBV compounds with novel antiviral mechanisms. In this manuscript, the natural products (polysaccharides and 165 compounds) with the activity of antihepatitis B virus are discussed according to their chemical classes, including 14 phenylpropanoids, 8 flavonoids,12 xanthones, 13 anthroquinones, 47 terpenoids, 6 alkaloids, 15 enediynes, 11 aromatics, 18 phenylalanine dipeptides compounds, and 13 others. In addition, the anti-HBV mechanism and targets of natural product were also discussed. The aim of this review is to report new discoveries about anti-HBV natural products and to provide reference for researchers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HBV life cycle and therapeutic targets. HBV life cycle: adsorption, penetration, biosynthesis, assembly, and secretion; therapeutic targets: entry inhibitors (NTCP and HSPG as the receptor-virus binding), cccDNA inhibitors (inhibiting the information of cccDNA), Epi-drugs (inhibiting the viral RNA synthesis), endoplasmic reticulum inhibitors (inhibiting the viral capsid assembly), and glucosidese inhibitors (inhibiting the secretion of HBV proteins).
Figure 2
Figure 2
Chemical structures of representative anti-HBV phenylpropanoids 1-14.
Figure 3
Figure 3
Chemical structures of representative anti-HBV flavonoids 15-22.
Figure 4
Figure 4
Chemical structures of representative anti-HBV xanthones 23-35.
Figure 5
Figure 5
Chemical structures of representative anti-HBV anthroquinones 36-49.
Figure 6
Figure 6
Chemical structures of representative anti-HBV terpenes 50-97.
Figure 7
Figure 7
Chemical structures of representative anti-HBV alkaloids 98-104.
Figure 8
Figure 8
Chemical structures of representative anti-HBV enediynes 105-120.
Figure 9
Figure 9
Chemical structures of representative anti-HB Varomatics 121-132.
Figure 10
Figure 10
Chemical structures of representative anti-HBV phenylalanine dipeptides 133-151.
Figure 11
Figure 11
Chemical structures of representative anti-HBV compounds 152-165.
See this image and copyright information in PMC

References

    1. Wohlfarth C., Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacologica Sinica. 2009;30(1):25–30. doi: 10.1038/aps.2008.5. - DOI - PMC - PubMed
    1. Safioleas M., Lygidakis N. J., Manti C. Hepatitis B today. Hepato-Gastroenterology. 2007;54(74):545–548. - PubMed
    1. World Health Organisation. Hepatitis B, factsheet, No.204. 2014. https://www.who.int/Mediacentre/factsheets/fs204/en/1.
    1. Mason W. S. Cancer Associated Viruses. New York: Springer-Verlag New York Inc.; 2012.
    1. Nassal M. New insights into HBV replication: new opportunities for improved therapies. Future Virology. 2009;4(1):55–70. doi: 10.2217/17460794.4.1.55. - DOI

LinkOut - more resources